Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins

Cancer Letters

Volumn 269, Issue 2, 2008, Pages 199-225

  Kunnumakkara, Ajaikumar B ^a   Anand, Preetha ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Curcumin; Inflammation; Molecular targets

Indexed keywords

6 PARADOL; ADALIMUMAB; BEVACIZUMAB; CAMPTOTHECIN; CAPSAICIN; CASSUMUIN A; CASSUMUIN B; CELECOXIB; CETUXIMAB; CURCUMIN; CYCLOCURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DEMETHOXYCURCUMIN; DIBENZOYLMETHANE DERIVATIVE; DIDEMETHOXYCURCUMIN; ENZYME; ETANERCEPT; GINGEROL; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; ISOEUGENOL; PACLITAXEL; PIPERINE; PLANT MEDICINAL PRODUCT; SORAFENIB; TRASTUZUMAB; TURMERIC; UNCLASSIFIED DRUG; YAKUCHINONE A;

ANGIOGENESIS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; DRUG STRUCTURE; GENE CONTROL; GLIOBLASTOMA; HELICOBACTER INFECTION; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; MELANOMA; METASTASIS; MOLECULAR INTERACTION; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; STOMACH CANCER; TUMOR XENOGRAFT;

ANIMALIA; CURCUMA LONGA; RODENTIA;

EID: 51349137454     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.009     Document Type: Review

References (146)

1. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
2. Jimeno A., and Hidalgo M. Multitargeted therapy: can promiscuity be praised in an era of political correctness?. Crit. Rev. Oncol. Hematol. 59 (2006) 150-158
3. Sams-Dodd F. Target-based drug discovery: is something wrong?. Drug Discov. Today 10 (2005) 139-147
4. Radulovic S., and Bjelogrlic S.K. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J. Buon. 12 Suppl 1 (2007) S151-S162
5. Aggarwal B.B., Surh Y.H., and Shishodia S. The molecular targets and therapeutics of curcumin in health and disease. Advances in Experimental Medicine and Biology vol. 995 (2007), Springer Publication
6. Vogel, Pelletier, J. Pharm. 2 (1818) 50.
7. Daybe F.V. Uber Curcumin. den Farbstoff der Curcumawurzzel Ber. 3 (1870) 609
8. Lampe V. Milobedzka. J. Ver. Dtsch. Chem. Ges. 46 (1913) 2235
9. Prasad K., Mantha S.V., Kalra J., and Lee P. Prevention of hypercholesterolemic atherosclerosis by garlic, an antixoidant. J. Cardiovasc. Pharmacol. Ther. 2 (1997) 309-320
10. Pan M.H., Huang T.M., and Lin J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 27 (1999) 486-494
11. Tomren M.A., Masson M., Loftsson T., and Tonnesen H.H. Studies on curcumin and curcuminoids XXXI. Symmetric and asymmetric curcuminoids: stability, activity and complexation with cyclodextrin. Int. J. Pharm. 338 (2007) 27-34
12. Sandur S.K., Pandey M.K., Sung B., Ahn K.S., Murakami A., Sethi G., Limtrakul P., Badmaev V., and Aggarwal B.B. Curcumin, demethoxycurcumin, bisdemothoxycurcumin, tetrahydrocurcumin, and turmerones differentially regulate anti-inflammatory and antiproliferative responses through a ROS-independent mechanism. Carcinogenesis 8 (2007) 1765-1773
13. Vadhan V.S., Weber D., Giralt S., Alexanian R., Thomas S., Zhou X., Patel P., Bueso-Ramos C., Newman R., and Aggarwal B.B. Curcumin downregulates NF-κB and related genes in patients with multiple myeloma: results of a phase1/2 study. Am. Soc. Hematol. (2007)
14. Dhillon N., Aggarwal B.B., Li L., Chiao P., Sarkar F., Wolff R.A., and Kurzrock R. Phase II trial of curcumin (diferuloyl methane), an NF-κB inhibitor, in patients with advanced pancreatic cancer. J. Clin. Oncol. 24 (2006) 14151
15. Bharti A.C., Donato N., and Aggarwal B.B. Curcumin diferuloylmethane inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. 7 (2003) 3863-3871
16. Aggarwal B.B., Bhatt I.D., Ichikawa H., Ahn K.S., Sethi G., Sandur S., Sundaram C., Seeram N., and Shishodia S. Curcumin-Biological and Medicinal Properties (2006), The CRC Press, Boca Raton, FL 297-368
17. Wang Z., Zhang Y., Banerjee S., Li Y., and Sarkar F.H. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106 (2006) 2503-2513
18. Park C.H., Hahm E.R., Park S., Kim H.K., and Yang C.H. The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett. 579 (2005) 2965-2971
19. Jaiswal A.S., Marlow B.P., Gupta N., and Narayan S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21 (2002) 8414-8427
20. Balasubramanyam K., Varier R.A., Altaf M., Swaminathan V., Siddappa N.B., Ranga U., and Kundu T.K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 279 (2004) 51163-51171
21. Marcu M.G., Jung Y.J., Lee S., Chung E.J., Lee M.J., Trepel J., and Neckers L. Curcumin is an inhibitor of p300 histone acetylatransferase. Med. Chem. 2 (2006) 169-174
22. Pendurthi U.R., and Rao L.V. Suppression of transcription factor Egr-1 by curcumin. Thromb. Res. 97 (2000) 179-189
23. Chen A., Xu J., and Johnson A.C. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 25 (2006) 278-287
24. Aggarwal B.B., Shishodia S., Takada Y., Jackson-Bernitsas D., Ahn K.S., Sethi G., and Ichikawa H. TNF blockade: an inflammatory issue. Ernst Schering Res. Found Workshop (2006) 161-186
25. Fu Y., Zheng S., Lin J., Ryerse J., and Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol. Pharmacol. 73 (2008) 399-409
26. Kuhad A., and Chopra K. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur. J. Pharmacol. 576 (2007) 34-42
27. Gulcubuk A., Altunatmaz K., Sonmez K., Haktanir-Yatkin D., Uzun H., Gurel A., and Aydin S. Effects of curcumin on tumour necrosis factor-alpha and interleukin-6 in the late phase of experimental acute pancreatitis. J. Vet. Med. A. Physiol. Pathol. Clin. Med. 53 (2006) 49-54
28. Singh S., and Aggarwal B.B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J. Biol. Chem. 270 (1995) 24995-25000
29. Dinarello C.A. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 25 (2006) 307-313
30. Cho J.W., Lee K.S., and Kim C.W. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int. J. Mol. Med. 19 (2007) 469-474
31. Ranjan D., Chen C., Johnston T.D., Jeon H., and Nagabhushan M. Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFkappaB activation, and IL-2 signaling. J. Surg. Res. 121 (2004) 171-177
32. Kobayashi T., Hashimoto S., and Horie T. Curcumin inhibition of Dermatophagoides farinea-induced interleukin-5 (IL-5) and granulocyte macrophage-colony stimulating factor (GM-CSF) production by lymphocytes from bronchial asthmatics. Biochem. Pharmacol. 54 (1997) 819-824
33. Fahey A.J., Adrian Robins R., and Constantinescu C.S. Curcumin modulation of IFN-beta and IL-12 signalling and cytokine induction in human T cells. J. Cell. Mol. Med. 11 (2007) 1129-1137
34. Grandjean-Laquerriere A., Antonicelli F., Gangloff S.C., Guenounou M., and Le Naour R. UVB-induced IL-18 production in human keratinocyte cell line NCTC 2544 through NF-kappaB activation. Cytokine 37 (2007) 76-83
35. Natarajan C., and Bright J.J. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12signaling through Janus kinase-STAT pathway in T lymphocytes. J. Immunol. 12 (2002) 6506-6513
36. Woo H.M., Kang J.H., Kawada T., Yoo H., Sung M.K., and Yu R. Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci. 80 (2007) 926-931
37. Tomita M., Holman B.J., Santoro C.P., and Santoro T.J. Astrocyte production of the chemokine macrophage inflammatory protein-2 is inhibited by the spice principle curcumin at the level of gene transcription. J. Neuroinflamm. 2 (2005) 8
38. Chen Y.R., and Tan T.H. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17 (1998) 173-178
39. Weir N.M., Selvendiran K., Kutala V.K., Tong L., Vishwanath S., Rajaram M., Tridandapani S., Anant S., and Kuppusamy P. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol. Ther. 6 (2007) 178-184
40. Reddy B.S. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ. Mol. Mutagen. 1 (2004) 26-35
41. Liu J.Y., Lin S.J., and Lin J.K. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 14 (1993) 857-861
42. Williams C.S., Mann M., and DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18 (1999) 7908-7916
43. Chun K.S., Keum Y.S., Han S.S., Song Y.S., Kim S.H., and Surh Y.J. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis 24 (2003) 1515-1524
44. Kunnumakkara A.B., Guha S., Krishnan S., Diagaradjane P., Gelovani J., and Aggarwal B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 67 (2007) 3853-3861
45. Aggarwal B.B., Shishodia S., Takada Y., Banerjee S., Newman R.A., Bueso-Ramos C.E., and Price J.E. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res. 11 (2005) 7490-7498
46. Kumar A., Dhawan S., Mukhopadhyay A., and Aggarwal B.B. Human immunodeficiency virus-1-tat induces matrix metalloproteinase-9 in monocytes through protein tyrosine phosphatase-mediated activation of nuclear transcription factor NF-kappaB. FEBS Lett. 462 (1999) 140-144
47. Lin Y.G., Kunnumakkara A.B., Nair A., Merritt W.M., Han L.Y., Armaiz-Pena G.N., Kamat A.A., Spannuth W.A., Gershenson D.M., Lutgendorf S.K., Aggarwal B.B., and Sood A.K. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin. Cancer Res. 13 (2007) 3423-3430
48. Camacho-Barquero L., Villegas I., Sánchez-Calvo J.M., Talero E., Sánchez-Fidalgo S., Motilva V., and Alarcón de la Lastra C. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int. Immunopharmacol. 3 (2007) 333-342
49. Kohl N.E., Omer C.A., Conner M.W., Anthony N.J., Davide J.P., deSolms S.J., Giuliani E.A., Gomez R.P., Graham S.L., Hamilton K., et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1 (1995) 792-797
50. Kortula L., Cheung J.Y., Mendelsohn J., and Kumar R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 18 (1995) 1741-1745
51. Mohan R., Sivak J., Ashton P., Russo L.A., Pham B.Q., Kasahara N., Raizman M.B., and Fini M.E. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J. Biol. Chem. 14 (2000) 10405-10412
52. Yang X., Thomas D.P., Zhang X., Culver B.W., Alexander B.M., Murdoch W.J., Rao M.N., Tulis D.A., Ren J., and Sreejayan N. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler. Thromb. Vasc. Biol. 1 (2006) 85-90
53. Zhou Y., Zheng S., Lin J., Zhang Q.J., and Chen A. The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPARgamma in rat activated hepatic stellate cell in vitro. Lab. Invest. 5 (2007) 488-498
54. Arbiser K.N.J.L., Rohan R., van Leeuwen R., Huang M.T., Fisher C., Flynn E., and HR B. Curcumin is an in vivo inhibitor of angiogenesis. Mol. Med. 4 6 (1998) 376-383
55. Gururaj B.M.A.E., Venkatesh D.A., Marmé D., and Salimath B.P. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem. Biophys. Res. Commun. 297 4 (2002) 934-942
56. Nakamura K., Yasunaga Y., Segawa T., Ko D., Moul J.W., Srivastava S., and Rhim J.S. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int. J. Oncol. 21 (2002) 825-830
57. Skommer J., Wlodkowic D., and Pelkonen J. Gene-expression profiling during curcumin-induced apoptosis reveals downregulation of CXCR4. Exp. Hematol. 35 (2007) 84-95
58. Herynk M.H., and Fuqua S.A. Estrogen receptors in resistance to hormone therapy. Adv. Exp. Med. Biol. 608 (2007) 130-143
59. Verma G.B., and Lin P.S. The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids. Environ. Health Perspect. 12 (1998) 807-812
60. Ohene-Abuakwa Y., and Pignatelli M. Adhesion molecules as diagnostic tools in tumor pathology. Int. J. Surg. Pathol. 8 (2000) 191-200
61. Gupta G.B.B. Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells. Int. J. Immunopharmacol. 11 (1999) 745-757
62. Dean E.J., Ranson M., Blackhall F., Holt S.V., and Dive C. Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treat Rev. 33 (2007) 203-212
63. el-Deiry T.T.W.S., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer K.K.W.E., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 4 (1993) 817-825
64. Liu E., Wu J., Cao W., Zhang J., Liu W., Jiang X., and Zhang X. Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J. Neurooncol. 85 (2007) 263-270
65. Shankar S., and Srivastava R.K. Involvement of Bcl-2 family members, phosphatidylinositol 3′-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int. J. Oncol. 30 (2007) 905-918
66. Choudhuri P.S.T., Das T., and Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J. Biol. Chem. 20 (2005) 20059-20068
67. Aggarwal B.B., Kumar A., and Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23 (2003) 363-398
68. Kamat A.M., Sethi G., and Aggarwal B.B. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol. Cancer Ther. 6 (2007) 1022-1030
69. Chendil D., Ranga R.S., Meigooni D., Sathishkumar S., and Ahmed M.M. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 23 (2004) 1599-1607
70. Goel A., Kunnumakkara A.B., and Aggarwal B.B. Curcumin as "Curecumin: from kitchen to clinic. Biochem. Pharmacol. 4 (2007) 787-809
71. Kuttan R., Bhanumathy P., Nirmala K., and George M.C. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 29 (1985) 197-202
72. Ruby A.J., Kuttan G., Babu K.D., Rajasekharan K.N., and Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett. 94 (1995) 79-83
73. Bachmeier B., Nerlich A.G., Iancu C.M., Cilli M., Schleicher E., Vene R., Dell'Eva R., Jochum M., Albini A., and Pfeffer U. The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol. Biochem. 19 (2007) 137-152
74. Li L., Ahmed B., Mehta K., and Kurzrock R. Liposomal curcumin with and without oxaliplat, effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol. Cancer Ther. 6 (2007) 1276-1282
75. Cui S.X., Qu X.J., Xie Y.Y., Zhou L., Nakata M., Makuuchi M., and Tang W. Curcumin inhibits telomerase activity in human cancer cell lines. Int. J. Mol. Med. 18 (2006) 227-231
76. Aoki H., Takada Y., Kondo S., Sawaya R., Aggarwal B.B., and Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol. Pharmacol. 72 (2007) 29-39
77. Ohashi Y., Tsuchiya Y., Koizumi K., Sakurai H., and Saiki I. Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. Oncology 65 (2003) 250-258
78. Busquets S., Carbo N., Almendro V., Quiles M.T., Lopez-Soriano F.J., and Argiles J.M. Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Lett. 167 (2001) 33-38
79. LoTempio M.M., Veena M.S., Steele H.L., Ramamurthy B., Ramalingam T.S., Cohen A.N., Chakrabarti R., Srivatsan E.S., and Wang M.B. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin. Cancer Res. 11 (2005) 6994-7002
80. Odot J., Albert P., Carlier A., Tarpin M., Devy J., and Madoulet C. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int. J. Cancer 111 (2004) 381-387
81. Menon L.G., Kuttan R., and Kuttan G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett. 95 (1995) 221-225
82. Menon L.G., Kuttan R., and Kuttan G. Anti-metastatic activity of curcumin and catechin. Cancer Lett. 141 (1999) 159-165
83. Li L., Braiteh F.S., and Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104 (2005) 1322-1331
84. Dorai T., Cao Y.C., Dorai B., Buttyan R., and Katz A.E. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47 (2001) 293-303
85. Hong J.H., Ahn K.S., Bae E., Jeon S.S., and Choi H.Y. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis. 9 (2006) 147-152
86. Li M., Zhang Z., Hill D.L., Wang H., and Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 67 (2007) 1988-1996
87. Anto R.J., Maliekal T.T., and Karunagaran D. L-929 cells harboring ectopically expressed RelA resist curcumin-induced apoptosis. J. Biol. Chem. 275 (2000) 15601-15604
88. Nagabhushan M., and Bhide S.V. Curcumin as an inhibitor of cancer. J. Am. Coll. Nutr. 11 (1992) 192-198
89. Soni K.B., and Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J. Physiol. Pharmacol. 36 (1992) 273-275
90. Shishu S.A., and Kaur IP. Inhibitory effect of curcumin and its natural analogues on genotoxicity of heterocyclic amines from cooked food. Indian J. Exp. Biol. 40 12 (2002) 1365-1372
91. Huang M.T., Lou Y.R., Xie J.G., Ma W., Lu Y.P., Yen P., Zhu B.T., Newmark H., and Ho C.T. Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis 19 (1998) 1697-1700
92. Singletary K., MacDonald C., Wallig M., and Fisher C. Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin. Cancer Lett. 103 (1996) 137-141
93. Pereira M.A., Grubbs C.J., Barnes L.H., Li H., Olson G.R., Eto I., Juliana M., Whitaker L.M., Kelloff G.J., Steele V.E., and Lubet R.A. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 17 (1996) 1305-1311
94. Deshpande S.S., and Maru G.B. Effects of curcumin on the formation of benzo[a]pyrene derived DNA adducts in vitro. Cancer Lett. 4 (1995) 71-80
95. Inano H., Onoda M., Inafuku N., Kubota M., Kamada Y., Osawa T., Kobayashi H., and Wakabayashi K. Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays. Carcinogenesis 20 (1999) 1011-1018
96. Inano H., and Onoda M. Radioprotective action of curcumin extracted from Curcuma longa LINN: inhibitory effect on formation of urinary 8-hydroxy-2′-deoxyguanosine, tumorigenesis, but not mortality, induced by gamma-ray irradiation. Int. J. Radiat. Oncol. Biol. Phys. 53 (2002) 735-743
97. Rao C.V., Simi B., and Reddy B.S. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 14 (1993) 2219-2225
98. Kim J.M., Kim D.J., Park C.B., Takasuka N., Baba-Toriyama H., Ota T., Nir Z., Khachik S.N.F., Tanaka Y., Osawa T., Uraji T., Murakoshi M., Nishino H., and Tsuda H. Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethylhydrazine initiation. Carcinogenesis 19 1 (1998) 81-85
99. Shpitz G.N.B., Sagiv E., Lev-Ari S., Liberman E., Kazanov D., and Arber N. Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 74 3-4 (2006) 140-144
100. Collett G.P., Robson C.N., Mathers J.C., and Campbell F.C. Curcumin modifies Apc(min) apoptosis resistance and inhibits 2-amino 1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) induced tumour formation in Apc(min) mice. Carcinogenesis 22 (2001) 821-825
101. Perkins S., Verschoyle R.D., Hill K., Parveen I., Threadgill M.D., Sharma R.A., Williams M.L., Steward W.P., and Gescher A.J. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 535-540
102. Ushida J., Sugie S., Kawabata K., Pham Q.V., Tanaka T., Fujii K., Takeuchi H., Ito Y., and Mori H. Chemopreventive effect of curcumin on N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. Jpn. J. Cancer Res. 91 (2000) 893-898
103. Huang M.T., Deschner E.E., Newmark H.L., Wang Z.Y., Ferraro T.A., and Conney A.H. Effect of dietary curcumin and ascorbyl palmitate on azoxymethanol-induced colonic epithelial cell proliferation and focal areas of dysplasia. Cancer Lett. 64 (1992) 117-121
104. Huang M.T., Lou Y.R., Ma W., Newmark H.L., Reuhl K.R., and Conney A.H. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 54 (1994) 5841-5847
105. Rao C.V., Rivenson A., Simi B., and Reddy B.S. Chemoprevention of colon cancer by dietary curcumin. Ann N. Y. Acad. Sci. 768 (1995) 201-204
106. Kwon Y., Malik M., and Magnuson B.A. Inhibition of colonic aberrant crypt foci by curcumin in rats is affected by age. Nutr. Cancer 48 (2004) 37-43
107. Sugimoto K., Hanai H., Tozawa K., Aoshi T., Uchijima M., Nagata T., and Koide Y. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123 (2002) 1912-1922
108. Ukil A., Maity S., Karmakar S., Datta N., Vedasiromoni J.R., and Das P.K. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br. J. Pharmacol. 139 (2003) 209-218
109. Venkataranganna M.V., Rafiq M., Gopumadhavan S., Peer G., Babu U.V., and Mitra S.K. NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene-induced colitis through down-regulation of NFkappa-B and iNOS. World J. Gastroenterol. 13 (2007) 1103-1107
110. Ikezaki S., Nishikawa A., Furukawa F., Kudo K., Nakamura H., Tamura K., and Mori H. Chemopreventive effects of curcumin on glandular stomach carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine and sodium chloride in rats. Anticancer Res. 21 (2001) 3407-3411
111. Tanaka T., Makita H., Ohnishi M., Hirose Y., Wang A., Mori H., Satoh K., Hara A., and Ogawa H. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperid comparison with the protective effect of beta-carotene. Cancer Res. 54 (1994) 4653-4659
112. Azuine M.A., and Bhide S.V. Adjuvant chemoprevention of experimental cancer: catechin and dietary turmeric in forestomach and oral cancer models. J. Ethnopharmacol. 44 (1994) 211-217
113. Chuang S.E., Cheng A.L., Lin J.K., and Kuo M.L. Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem. Toxicol. 38 (2000) 991-995
114. Hecht S.S., Kenney P.M., Wang M., Trushin N., Agarwal S., Rao A.V., and Upadhyaya P. Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett. 137 (1999) 123-130
115. Huang M.T., Smart R.C., Wong C.Q., and Conney A.H. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 48 (1988) 5941-5946
116. Huang M.T., Ma W., Yen P., Xie J.G., Han J., Frenkel K., Grunberger D., and Conney A.H. Inhibitory effects of topical application of low doses of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis. Carcinogenesis 18 (1997) 83-88
117. Ishizaki C., Oguro T., Yoshida T., Wen C.Q., Sueki H., and Iijima M. Enhancing effect of ultraviolet A on ornithine decarboxylase induction and dermatitis evoked by 12-O-tetradecanoylphorbol-13-acetate and its inhibition by curcumin in mouse skin. Dermatology 193 (1996) 311-317
118. Soudamini K.K., and Kuttan R. Inhibition of chemical carcinogenesis by curcumin. J. Ethnopharmacol. 27 (1989) 227-233
119. Lu Y.P., Chang R.L., Huang M.T., and Conney A.H. Inhibitory effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced increase in ornithine decarboxylase mRNA in mouse epidermis. Carcinogenesis 14 (1993) 293-297
120. Ichiki K., Mitani N., Doki Y., Hara H., Misaki T., and Saiki I. Regulation of activator protein-1 activity in the mediastinal lymph node metastasis of lung cancer. Clin. Exp. Metastasis 18 (2000) 539-545
121. Wahlstrom B., and Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol. Toxicol. (Copenh.) 43 (1978) 86-92
122. Ireson C., Orr S., Jones D.J., Verschoyle R., Lim C.K., Luo J.L., Howells L., Plummer S., Jukes R., Williams M., Steward W.P., and Gescher A. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 61 (2001) 1058-1064
123. Maiti K., Mukherjee K., Gantait A., Saha B.P., and Mukherjee P.K. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm. 330 (2007) 155-163
124. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., and Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 64 (1998) 353-356
125. Mosley C.A., Liotta D.C., and Snyder J.P. Highly active anticancer curcumin analogues. Adv. Exp. Med. Biol. 595 (2007) 77-103
126. Ma Z., Shayeganpour A., Brocks D.R., Lavasanifar A., and Samuel J. High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomed. Chromatogr. 21 (2007) 546-552
127. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A., and Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin): a novel strategy for human cancer therapy. J. Nanobiotechnol. 5 (2007) 3
128. Liu A., Lou H., Zhao L., and Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J. Pharm. Biomed. Anal. 40 (2006) 720-727
129. Anand P., Kunnumakkara A.B., Newman R.A., and Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4 (2007) 807-818
130. Sharma R.A., McLelland H.R., Hill K.A., Ireson C.R., Euden S.A., Manson M.M., Pirmohamed M., Marnett L.J., Gescher A.J., and Steward W.P. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 7 (2001) 1894-1900
131. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., Marczylo T.H., Morgan B., Hemingway D., Plummer S.M., Pirmohamed M., Gescher A.J., and Steward W.P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 10 (2004) 6847-6854
132. Garcea G., Berry D.P., Jones D.J., Singh R., Dennison A.R., Farmer P.B., Sharma R.A., Steward W.P., and Gescher A.J. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 120-125
133. Holt P.R., Katz S., and Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig. Dis. Sci. 50 (2005) 2191-2193
134. Kuttan R., Sudheeran P.C., and Josph C.D. Turmeric and curcumin as topical agents in cancer therapy. Tumori 73 (1987) 29-31
135. Cruz-Correa M., Shoskes D.A., Sanchez P., Zhao R., Hylind L.M., Wexner S.D., and Giardiello F.M. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin. Gastroenterol. Hepatol. 4 (2006) 1035-1038
136. Di Mario F., Cavallaro L.G., Nouvenne A., Stefani N., Cavestro G.M., Iori V., Maino M., Comparato G., Fanigliulo L., Morana E., Pilotto A., Martelli L., Martelli M., Leandro G., and Franze A. A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure?. Helicobacter 12 (2007) 238-243
137. Lal B., Kapoor A.K., Agrawal P.K., Asthana O.P., and Srimal R.C. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother. Res. 14 (2000) 443-447
138. Bundy R., Walker A.F., Middleton R.W., and Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J. Altern. Complem. Med. 10 (2004) 1015-1018
139. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai M.K., Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., and Hsieh C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21 (2001) 2895-2900
140. Durgaprasad S., Pai C.G., Vasanthkumar, Alvres J.F., and Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J. Med. Res. 122 (2005) 315-318
141. Rafailov S., Cammack S., Stone B.A., and Katz A.E. The role of zyflamend, an herbal anti-inflammatory, as a potential chemopreventive agent against prostate cancer: a case report. Integr. Cancer Ther. 6 (2007) 74-76
142. Hanai H., Iida T., Takeuchi K., Watanabe F., Maruyama Y., Andoh A., Tsujikawa T., Fujiyama Y., Mitsuyama K., Sata M., Yamada M., Iwaoka Y., Kanke K., Hiraishi H., Hirayama K., Arai H., Yoshii S., Uchijima M., Nagata T., and Koide Y. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 4 (2006) 1502-1506
143. Garcea G., Jones D.J., Singh R., Dennison A.R., Farmer P.B., Sharma R.A., Steward W.P., Gescher A.J., and Berry D.P. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br. J. Cancer 90 (2004) 1011-1015
144. Plummer S.M., Hill K.A., Festing M.F., Steward W.P., Gescher A.J., and Sharma R.A. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol. Biomarkers Prev. 10 (2001) 1295-1299
145. Kurd S.K., Smith N., VanVoorhees A., Troxel A.B., Badmaev V., Seykora J.T., and Gelfand J.M. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. J. Am. Acad. Dermatol. 58 (2008) 625-631
146. Lin C.C., Lu Y.P., Lou Y.R., Ho C.T., Newmark H.H., MacDonald C., Singletary K.W., and Huang M.T. Inhibition by dietary dibenzoylmethane of mammary gland proliferation, formation of DMBA-DNA adducts in mammary glands, and mammary tumorigenesis in Sencar mice. Cancer Lett. 168 (2001) 125-132